A Sugar Ring for Niemann-Pick Type C Won FDA Approval After Its Only Randomized Trial Failed
The FDA says 36 children on adrabetadex reached a median survival of 8.5 years, against 4.9 in matched outside controls. Its only randomized trial missed, its price is unannounced, and its label warns of permanent hearing loss.
8.5 years Adrabetadex